Collectionner le produit
Détails du produit
Synonyms
GSK3B, Glycogen synthase kinase-3 beta
Source
Human GSK-3beta, His Tag (GSB-H5545) is expressed from Baculovirus-Insect cells. It contains AA Met 1 - Thr 420 (Accession # P49841-1).
Predicted N-terminus: Met
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 48.8 kDa. The protein migrates as 49-53 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Human GSK-3beta, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Human GSK-3beta, His Tag (Cat. No. GSB-H5545) is more than 95% and the molecular weight of this protein is around 48-65 kDa verified by SEC-MALS.
Report
Bioactivity
The specific activity of GSK-3beta was determined to be >120 pmol/min/ug by ADP-Glo™ Kinase Assay using a synthetic substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE) (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Glycogen synthase kinase-3 beta
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
5 Détails
- Étape de développement la plus élevée：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
